All In Biotech

Drug Trial Radar · NCT01360554

ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer

Archer 1009:a Randomized, Double Blind Phase 3 Efficacy And Safety Study Of Pf-00299804 (Dacomitinib) Versus Erlotinib For The Treatment Of Advanced Non-small Cell Lung Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy

Last checked: Nov 20, 2026Latest source record: May 24, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 878 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

878

Actual

Start

Jun 16, 2011

Primary completion

Sep 30, 2013

Study completion Sep 14, 2015

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
May 25, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multinational, multicenter, randomized,double-blinded, Phase 3 study comparing the efficacy and safety of treatment with PF-00299804 to treatment with erlotinib in patients with advanced non-small cell lung cancer, previously treated with at least one prior regimen. Analyses of primary objective (Progression Free Survival) will be done in two co-primary populations as defined in the protocol.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • Dacomitinib (PF-00299804)Drug

    Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing

  • Active Comparator (erlotinib)Drug

    Active comparator (erlotinib) provided as 150 mg tablet, continuous oral daily dosing

  • Placebo erlotinibDrug

    placebo erlotinib, provided as 150 mg tablet, continuous oral daily dosing.

  • Placebo PF00299804Drug

    placebo PF-00299804, provide as 45 mg tablet, continuous oral daily dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) Per Independent Radiologic Review.Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, participants were followed up until progressive disease regardless of start of subsequent cancer therapy.
  2. Progression-Free Survival (PFS) Per Independent Radiologic Review in KRAS Wild-type (WT) Participants.Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, participants were followed up until progressive disease regardless of start of subsequent cancer therapy.

Locations

224 sites in 23 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Northwest Alabama Cancer Center

    Florence, Alabama

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama

  • University of South Alabama Medical Center

    Mobile, Alabama

  • Northwest Alabama Cancer Center

    Muscle Shoals, Alabama

  • Ironwood physicians P C dba Ironwood Cancer & Research Centers

    Chandler, Arizona

  • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers

    Chandler, Arizona

  • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers

    Gilbert, Arizona

  • Desert Oncology Associates dba Ironwood Cancer and Research Centers

    Mesa, Arizona

  • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers

    Mesa, Arizona

  • Highlands Oncology Group PA

    Fayetteville, Arkansas

  • Highlands Oncology Group, PA

    Rogers, Arkansas

  • Central Hematology Oncology Medical Group Inc.

    Alhambra, California

  • UCLA Hematology Oncology-Alhambra

    Alhambra, California

  • City of Hope

    Duarte, California

  • St. Jude Heritage Healthcare

    Fullerton, California

  • Drug Management Only

    Los Angeles, California

  • Drug Managerrent Only:

    Los Angeles, California

  • UCLA West Medical Pharmacy

    Los Angeles, California

  • Administrative Address: UCLA Hematology Oncology-Clinical Research Unit (CRU)

    Los Angeles, California

  • Drug Shipment Address: Ronald Reagan UCLA Medical Center, Drug Information Center

    Los Angeles, California

  • Regulatory Management Only:

    Los Angeles, California

  • Regulatory Management:

    Los Angeles, California

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

  • TORI Central Administration

    Los Angeles, California

  • Westwood Bowyer Clinic, Peter Morton Medical Building

    Los Angeles, California

  • UCLA/Pasadena Healthcare Hematology-Oncology

    Pasadena, California

  • Central Hematology Oncology Medical Group, Inc.

    Pasadena, California

  • Cancer Care Associates Medical Group Inc.

    Redondo Beach, California

  • Central Coast Medical Oncology Corporation

    Santa Maria, California

  • UCLA Hematology Oncology-Parkside

    Santa Monica, California

  • UCLA Hematology Oncology-Santa Monica

    Santa Monica, California

  • UCLA Santa Monica Medical Center & Orthopedic Hospital

    Santa Monica, California

  • City of Hope South Pasadena Cancer Center

    South Pasadena, California

  • UCLA/Santa Clarita Valley Cancer Center

    Valencia, California

  • UCLA Cancer Center

    Westlake Village, California

  • Norwalk Hospital

    Norwalk, Connecticut

  • Florida Hospital

    Orlando, Florida

Showing 40 of 224 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.